Abpro, Atlantic Coastal Acquisition Corp. II과의 사업 결합 계약과 관련해 S-4 양식의 증권 신고서 제출 발표
January 22, 2024 12:51 ET
|
Abpro Corporation
매사추세츠주 우번 & 뉴욕, Jan. 23, 2024 (GLOBE NEWSWIRE) -- 차세대 항체 치료제를 통해 치명적인 중증 질환에 직면한 인류의 삶을 개선해 나간다는 사명을 갖고 있는 Abpro Corporation (이하 "Abpro")와 특수목적 인수기업인 Atlantic Coastal Acquisition Corp. II (나스닥:...
Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II
January 22, 2024 08:00 ET
|
Abpro Corporation
WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening...
Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant
December 09, 2021 08:00 ET
|
Abpro Corporation
Preclinical pseudovirus data and structural modeling shows ABP 310 retains activity and potency against the SARS-CoV-2 Omicron variant mutationsABP 310 EUA possible as early as 2022 WOBURN, Mass.,...
Abpro Announces Presentation and Data at the 2021 Annual Association for Research in Vision and Ophthalmology of ABP201 for the Treatment of Wet Age-related Macular Degeneration
May 04, 2021 08:00 ET
|
Abpro Corporation
Data showed reduction of neovascular lesion formation and vascular leakage in a rodent model of choroidal neovascularizationABP201 performed equally or better than aflibercept in lesion inhibition and...
Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19
February 02, 2021 08:00 ET
|
Abpro Corporation
• Results of this study showed safety and pharmacokinetic data at doses from 4 mg/kg to 60 mg/kg • Phase 2/3 registrational studies have been initiated WOBURN, Mass., Feb. 02, 2021 (GLOBE...
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19
December 16, 2020 08:30 ET
|
Abpro Corporation
ABP 300 is a novel human antibody therapy that has been shown to neutralize COVID-19 in preclinical in vivo studiesPivotal/Registrational studies will assess safety, tolerability, efficacy, and...
Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders
November 25, 2020 08:00 ET
|
Abpro Corporation
WOBURN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Abpro Corporation today announced the expansion of its scientific advisory board with additions of infectious disease drug development leaders. The...
Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19
November 16, 2020 08:00 ET
|
Abpro Corporation
▪ Data from the monkey challenge study published in Nature Communications showed a single dose of neutralizing antibody ABP 300 blocks infection of SARS-CoV-2 in prophylactic treatment and clears...
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19
October 20, 2020 08:00 ET
|
Abpro Corporation
ABP 300 is a novel human antibody therapy that has been shown to neutralize COVID-19 in preclinical in vivo studies Study enrolled 42 subjects and results are expected in Q1 2021 WOBURN, Mass., Oct....
Abpro 建立策略合作夥伴關係以在亞洲市場推動兩個雙特異性抗體候選產品
March 03, 2020 11:15 ET
|
Abpro Corporation
Abpro 將獲得最多 11 億美元，其中包括 3,000 萬美元的前期股權投資、臨床資金、里程碑和特許權使用費 Abpro 授予前身為 Ugint Co. Ltd 的 Abpro Bio 獨家許可權，以在包括大中華地區、日本和韓國在內的亞洲市場開發和商業化 ABP-100 和 ABP-201 當中包含兩個屬於免疫腫瘤學和眼科的雙特異性抗體候選產品 馬薩諸塞州沃伯恩, March 04,...